A Phase I/IIa study of MAGE-A1-specific TCR-transduced T cells in patients with relapsed/refractory multiple myeloma
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2017
At a glance
- Drugs MAGEA1 TCR (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 06 Sep 2017 Trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
- 03 Aug 2017 According to Medigene media release, the company expects Clinical trial authorization and initiation in 2017.
- 23 Mar 2017 According to Medigene media release, Federal Ministry of Education and Research (BMBF) will be the sponsor of this trial.